
³»ºÐºñ¿Ü°úÇÐ
- ÀúÀÚ(±Û)´ëÇѰ©»ó¼±³»ºÐ¿Ü°úÇÐȸ
- ÃâÆÇ»ç±ºÀÚÃâÆÇ»ç
- ¹ßÇàÀÏ2018³â
ÃÖ¼Ò ¹üÀ§ À¯¹æÁ¾¾ç ¼ö¼úÀÇ ´ë°¡
ÁÖ¿ä Áø·á ºÐ¾ß´Â À¯¹æ¾Ï, °©»ó¼±¾Ï, ºÎ½ÅÁúȯÀÌ´Ù. À¯¹æ¾Ï ´ÙÇÐÁ¦ÆÀÀ» ±¸¼ºÇϰí À¯ÀüÀÚ ºÐ¼®À» ÅëÇØ °¢°¢ÀÇ È¯ÀÚ¿¡°Ô °¡Àå ºü¸£°í ¿Ïº®ÇÑ Ä¡·á¸¦ Á¦°øÇϱâ À§ÇØ ³ë·ÂÇÏ´Â ÀÇ»ç´Ù. ´ë³»¿ÜÀûÀ¸·Î Ȱ¹ßÇÑ ¿¬±¸È°µ¿À» ÅëÇØ ±¹Á¦À¯¹æ¾Ï½ÉÆ÷Áö¿ò ¹× Çѱ¹À¯¹æ¾ÏÇÐȸ¿¡¼ ÃÖ¿ì¼ö³í¹® Çмú»óÀ» ¼ö»óÇß´Ù.
Á¦ ¸ñ | À¯¹æÇÐ | ||
---|---|---|---|
ÃâÆÇ»ç | ÆäÀÌÁö¿ø | ¹ßÇàÀÏ | 2017³â |
Á¦ ¸ñ | An observational, prospective , open labe, multicenter study to evaluate the safety and effectiveness of Prefilgrastim as secondary prophylaxis to decrease the incidence of febrile neutropenia in Korean female patients with breast cancer. | ||
---|---|---|---|
¹ßÇ¥³âµµ | 2023 | ¹ßÇ¥Áö | Breast |
Á¦ ¸ñ | Clinical significance of HER2-low expression in early breast cancer: a nationwide study from the Korean Breast Cancer Society | ||
---|---|---|---|
¹ßÇ¥³âµµ | 2022 | ¹ßÇ¥Áö | BREAST CANCER RESEARCH |
Á¦ ¸ñ | Label-free breast cancer detection using fiber probe-based Raman spectrochemical biomarker-dominated profiles extracted from a mixture analysis algorithm | ||
---|---|---|---|
¹ßÇ¥³âµµ | 2021 | ¹ßÇ¥Áö | Analytical Methods |
Á¦ ¸ñ | Response to neoadjuvant chemotherapy based on pathologic complete response in very young patients with ER-positive breast cancer: a large, multicenter, observational study | ||
---|---|---|---|
¹ßÇ¥³âµµ | 2021 | ¹ßÇ¥Áö | BMC CANCER |
Á¦ ¸ñ | Clinical Outcomes Following Letrozole Treatment according to Estrogen Receptor Expression in Postmenopausal Women: LETTER Study (KBCSG-006) | ||
---|---|---|---|
¹ßÇ¥³âµµ | 2021 | ¹ßÇ¥Áö | Journal of Breast Cancer |
Á¦ ¸ñ | Clinical Significance of Receptor-Interacting Protein 3 and Parkin, Essential Molecules for Necroptosis, in Breast Cancer | ||
---|---|---|---|
¹ßÇ¥³âµµ | 2021 | ¹ßÇ¥Áö | Journal of Breast Cancer |
* ¾ÏÁٱ⼼Æ÷ ¿¬±¸¸¦ ÅëÇÑ Áø´Ü°ú Ä¡·á* À¯¹æ¾Ï ´ÙÇÐÁ¦ÆÀÀ» ±¸¼ºÇϰí À¯ÀüÀÚ ºÐ¼®À» ÅëÇØ °¢°¢ÀÇ È¯ÀÚ¿¡°Ô °¡Àå ºü¸£°í ¿Ïº®ÇÑ Ä¡·á¸¦ Á¦°øÇϱâ À§ÇØ ³ë·ÂÇÏ´Â ÀÇ»ç´Ù. ´ë³»¿ÜÀûÀ¸·Î Ȱ¹ßÇÑ ¿¬±¸È°µ¿À» ÅëÇØ ±¹Á¦À¯¹æ¾Ï½ÉÆ÷Áö¿ò ¹× Çѱ¹À¯¹æ¾ÏÇÐȸ¿¡¼ ÃÖ¿ì¼ö³í¹® Çмú»óÀ» ¼ö»óÇß´Ù.
À¯¹æ°©»ó¼±Àº ¿Ü°úºÐ¾ß¿¡¼ ¿©¼ºÀÌ ´ëºÎºÐ ÀÔ´Ï´Ù. ȯÀÚµéÀÇ ±Ã±ÝÁõ°ú Áú¹®À» ¸íÄèÇÏ°Ô ÇØ°áÇØ ÁÖ´Â °Í, ¸¶À½À» Çì¾Æ¸®´Â ÀμúÀ» ³õÄ¡Áö ¾Ê´Â °ÍÀ̶ó°í »ý°¢ÇÕ´Ï´Ù. ¾Æ¹«¸® ÁÁÀº ÀÇ·á ½Ã½ºÅÛ°ú ¼ú±â°¡ À־ ȯÀÚÀÇ ¸¶À½À» ¾î·ç¸¸Áö´Â °ÍÀ» Àؾ ¾È µÈ´Ù´Â °Í. ¶ÇÇÑ 3ºÐ Áø·á´Â ¾ø´Ù¶ó´Â ¸¶À½À¸·Î ȯÀÚ¿Í Áö¼ÓÀûÀ¸·Î Ä¿¹Â´ÏÄÉÀ̼ÇÇÏ°í ¾ðÁ¦³ª Ä£ÀýÀ» ÀÒÁö ¾Ê°í Áø·á¸¦ º¸´Â°Ô ÃÖ°íÀÇ Ä¡·á¹ýÀ̶ó°í »ý°¢ÇÕ´Ï´Ù.
°µ¿°æÈñ´ëÇб³º´¿øÀº Àǰú, ÇÑÀǰú, Ä¡°ú´ëÇÐÀ» ¸ðµÎ º¸À¯ÇÑ º´¿øÀ¸·Î, 3°³ ´ëÇк´¿øÀÇ ¼öÁØ ³ôÀº ÀǷἺñ½º¸¦ ÇÑ ¹ø¿¡ ¹ÞÀ» ¼ö ÀÖ´Ù. ¿¬¸éÀû 24,000¿© Æò º»°ü Áö»ó 14Ãþ, º°°ü Áö»ó 4ÃþÀÇ 800º´»óÀ» °®Ãè´Ù. ³úÁúȯ¡¤°üÀý¡¤Ã´Ãß µî Áúȯ Áß½ÉÀ¸·Î Æ¯ÈµÈ ÇùÁø ÀÇ·á
¼ºñ½º¸¦ Á¦°øÇÏ´Â ÀÇ¡¤ÇÑ ÇùÁø¼¾ÅÍ, ȯÀÚ ¼¼°è ÃÖ°í ¼öÁØÀÇ Áø·á½Ã½ºÅÛÀ» °®Ãá Àǰú
´ëÇк´¿ø, ÇÑÀÇÇÐÀ» ¼±µµÇÏ´Â ÇÑ¹æ ºê·£µåÆÄÀ§ 1À§ ÇÑÀǰú´ëÇк´¿ø¿Í Àü¹®¼º°ú ÆíÀǼºÀ» °®Ãá ȯÀÚ¸¸Á· º´¿øÀÎ Ä¡°ú´ëÇк´¿øÀÌ ÃÖ»óÀÇ ÀǷἺñ½º¸¦ Á¦°øÇϰí ÀÖ´Ù.
¼¿ïƯº°½Ã °µ¿±¸ µ¿³²·Î 892